drugset
Drugs / glenzocimab
last change Sep 2026 re-read 3 minutes ago

glenzocimab

also known as ACT017

Protein / enzyme biologic targets GP6 via inhibition

Developed for
ischemic stroke · acute respiratory distress syndrome · COVID-19
Investigated by
Acticor Biotech · Assistance Publique - Hôpitaux de Paris · Fondation Ophtalmologique Adolphe de Rothschild

Trials 5

today NCT06437431 · Ph 2/3 NCT05559398 · Ph 2/3 NCT05070260 · Ph 2/3 NCT04659109 · Ph 2 NCT03803007 · Ph 1/2
2019202020212022202320242025202620272028202920302031
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial · 1 met primary
Phase 1/2 NCT03803007 Mar 2019 → Sep 2021 ischemic stroke Acticor Biotech Completed Met primary
Phase 21 trial
Phase 2 NCT04659109 Dec 2020 → Aug 2021 COVID-19, acute respiratory distress syndrome Acticor Biotech Completed No outcome recorded
Phase 2/33 trials · 1 missed
Phase 2/3 NCT06437431 Sep 2026 → Oct 2030 expected ischemic stroke Fondation Ophtalmologique Adolphe de Rothschild Not yet recruiting No outcome recorded
Phase 2/3 NCT05559398 Jan 2023 → Jul 2025 ischemic stroke Assistance Publique - Hôpitaux de Paris Completed No outcome recorded
Phase 2/3 NCT05070260 Sep 2021 → Apr 2024 ischemic stroke Acticor Biotech Completed Missed primary

News releases announcing trial results or a regulatory action · 7

DateIssuerRelease
2022-07-21 Acticor Biotech Regulatory Acticor Biotech obtains "PRIME" status from the European Medicines Agency for glenzocimab in the treatment of stroke acticor-biotech.com ↗
2022-02-22 Acticor Biotech Results Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS) acticor-biotech.com ↗
That endpoint was achieved for all patients in the study (phases 1b and 2a combined).
2021-11-04 Acticor Biotech Regulatory Acticor Biotech Announces FDA Acceptance of IND Application for glenzocimab in Acute Ischemic Stroke acticor-biotech.com ↗
2020-10-01 Acticor Biotech Results Acticor Biotech Announces the Success of the First Phase of its ACTIMIS study with Glenzocimab In Patients with Acute Ischemic Stroke acticor-biotech.com ↗
The Drug Safety Monitoring Board (DSMB) confirmed the safety of the 1000mg Target Dose.
2018-04-25 Acticor Biotech Regulatory ACTICOR BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE acticor-biotech.com ↗
The final advice given by the Committee for Medicinal Product for Human use (CHMP) based on the questions and supporting discussion was very positive.
2018-02-05 Acticor Biotech Results ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ENDPOINTS acticor-biotech.com ↗
The primary endpoint assessing safety and tolerability was achieved with no serious adverse event reported at any of the doses tested.
2017-10-17 Acticor Biotech Regulatory Acticor Biotech first-in-human clinical trial in healthy volunteers acticor-biotech.com ↗

All press releases naming this drug 8 releases

DateIssuerRelease

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as glenzocimab “Glenzocimab is an antibody fragment that inhibits the action of platelet glycoprotein VI.” PMID 38267188 ↗ Feb 2024
4

NCT04659109 ↗

NCT05559398 ↗

NCT05070260 ↗

NCT06437431 ↗
Known as ACT017 “Glenzocimab (ACT-017, Acticor Biotech) is formulated for IV administration as a sterile product with 20 mM sodium citrate and 130 mM sodium chloride buffer at pH of 5.0.” NCT05559398 ↗
2

“Intravenous glenzocimab (ACT017) 1000 mg” NCT05070260 ↗

“Intravenous glenzocimab (ACT017) 1000 mg” NCT03803007 ↗
Action Inhibit “inhibits the action of platelet glycoprotein VI” PMID 38267188 ↗ Feb 2024
1

“Platelet glycoprotein VI (GPVI) inhibitor” CHEMBL4650395 ↗
Modality Protein / enzyme biologic “Glenzocimab is an antibody fragment” PMID 38267188 ↗ Feb 2024
Route Intravenous “Glenzocimab will be administered by IV infusion.” NCT04659109 ↗
Target GP6 “Platelet glycoprotein VI (GPVI) inhibitor” CHEMBL4650395 ↗